Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oftalmil
- Development stage
- Unknown
- Lead developer
- Bruschettini
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
Oftalmil is an approved ophthalmic solution developed and marketed by Bruschettini. It is a fixed-dose combination of naphazoline hydrochloride, a sympathomimetic vasoconstrictor, and zinc phenolsulfonate (also known as zinc sulfophenate), an astringent and antiseptic agent. Oftalmil is indicated for the treatment of alterations of the ocular surface, specifically to relieve eye redness, irritation, congestion, the sensation of a foreign body, and eyelid heaviness. Naphazoline acts as an agonist on alpha-adrenergic receptors to induce vasoconstriction of conjunctival blood vessels, thereby reducing congestion and redness. Zinc phenolsulfonate provides local astringent and mild antiseptic properties to soothe the ocular surface.
- Brand names
- Oftalmil
- Other names
- Oftalmil Collirionaphazoline + zinc phenolsulfonatenaphazoline hydrochloride + zinc phenolsulfonatenaphazoline hydrochloride + zinc sulfophenate
02
Targets
ADRA1A (α1A)ADRA2A (α2A)
Beyond the preview
Go deeper on Oftalmil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Oftalmil.